Last reviewed · How we verify
Thallous Chloride T1-201
Thallous chloride T1-201 is a potassium analog that accumulates in viable myocardial tissue and is used as a radiotracer for cardiac imaging.
Thallous chloride T1-201 is a potassium analog that accumulates in viable myocardial tissue and is used as a radiotracer for cardiac imaging. Used for Myocardial perfusion imaging for detection of coronary artery disease, Assessment of myocardial viability in patients with coronary artery disease.
At a glance
| Generic name | Thallous Chloride T1-201 |
|---|---|
| Sponsor | GE Healthcare |
| Drug class | Cardiac imaging agent |
| Target | Na+/K+-ATPase pump |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Thallium-201 mimics potassium and is taken up by the Na+/K+-ATPase pump in viable cardiac myocytes. The distribution of the radiotracer reflects regional myocardial blood flow and cellular viability, allowing visualization of perfusion defects and ischemic or infarcted tissue. It is used in nuclear medicine imaging to assess coronary artery disease and myocardial viability.
Approved indications
- Myocardial perfusion imaging for detection of coronary artery disease
- Assessment of myocardial viability in patients with coronary artery disease
Common side effects
- Radiation exposure
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thallous Chloride T1-201 CI brief — competitive landscape report
- Thallous Chloride T1-201 updates RSS · CI watch RSS
- GE Healthcare portfolio CI